No annual revenue total was found in NAUTILUS BIOTECHNOLOGY, INC.'s SEC filings.
Nautilus Biotechnology, Inc. (NAUT) files with the SEC under industry code 3826, Laboratory Analytical Instruments. Free cash flow was -$52.0 million. As of Sep 30, 2026 it held $114.3 million in cash and investments and $26.7 million in total debt.
Revenue
—
Net income (TTM)
$-58.58M
+6.7% vs year-ago TTM
Operating cash flow (TTM)
$-52.48M
+0.3% vs year-ago TTM
Free cash flow (TTM)
$-55.13M
-2.3% vs year-ago TTM
EPS (TTM)
$-0.46
+7.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
126.56M
+0.3% vs prior year
Net cash
$87.60M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- NAUT (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1808805
- Former names
- ARYA Sciences Acquisition Corp III (until Jun 8, 2021)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M | -$50.3M |
| Diluted EPS | -$0.47 | -$0.56 | -$0.51 | -$0.46 | -$0.60 |
| Operating cash flow | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
| Stockholders' equity | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M |
| Cash and investments | $156.1M | $206.3M | $264.1M | $313.6M | $362.1M |
| Total debt | $30.0M | $30.5M | $34.6M | $30.3M | $30.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended
|
Sep 11, 2026 | Sep 11, 2026 |
| 10-Q | Quarterly report | Jul 28, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
All 328 Nautilus Biotechnology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.